UroGen Pharma Ltd. (URGN)

Market Cap	929.83M +66.3%
Revenue (ttm)	109.79M +21.5%
Net Income	-153.49M
EPS	-3.19
Shares Out	48.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	911,373
Open	19.55
Previous Close	18.03
Day's Range	18.25 - 19.55
52-Week Range	3.42 - 30.00
Beta	1.44
Analysts	Strong Buy
Price Target	29.29 (+53.35%)
Earnings Date	May 11, 2026

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 291
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN
• Website: https://www.urogen.com

Financial Performance

In 2025, UroGen Pharma's revenue was $109.79 million, an increase of 21.45% compared to the previous year's $90.40 million. Losses were -$153.49 million, 21.0% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price target is $29.29, which is an increase of 53.35% from the latest price.

Price Target

$29.29

(53.35% upside)

Analyst Consensus: Strong Buy